Biotech Values

[rfj1862]

>Selzentry (a.k.a. maraviroc) is one of the cleverest pharmaceutical brand names in a while, IMO. Since the drug works on a host mechanism, it ought to be shielded from mutations in the HIV virus.<

Um, no. In the presence of maraviroc, CXCR4-dependent virus already present in the infected individual will be selected or escape mutants will shift to a CXCR4-dependent mechanism of entry. Even if you were to hypothetically treat a patient with both a CCR5 and a CXCR4 antagonist, HIV can use still mutate to use other mechanisms for entry.